119 related articles for article (PubMed ID: 23295976)
1. 17-hydroxy progesterone caproate for preterm labor prevention: final blood levels.
Usta IM; Usta J; Nassar AH
Am J Obstet Gynecol; 2013 Apr; 208(4):337. PubMed ID: 23295976
[No Abstract] [Full Text] [Related]
2. Reply: To PMID 23295976.
Caritis SN
Am J Obstet Gynecol; 2013 Apr; 208(4):337-8. PubMed ID: 23295980
[No Abstract] [Full Text] [Related]
3. Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation.
Caritis SN; Simhan HN; Zhao Y; Rouse DJ; Peaceman AM; Sciscione A; Spong CY; Varner MW; Malone FD; Iams JD; Mercer BM; Thorp JM; Sorokin Y; Carpenter M; Lo J; Ramin SM; Harper M;
Am J Obstet Gynecol; 2012 Nov; 207(5):396.e1-8. PubMed ID: 22959763
[TBL] [Abstract][Full Text] [Related]
4. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?
Hall NR
Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799
[TBL] [Abstract][Full Text] [Related]
5. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
O'Brien JM; Lewis DF
Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
[TBL] [Abstract][Full Text] [Related]
6. Iatrogenic autoimmune progesterone dermatitis caused by 17alpha-hydroxyprogesterone caproate for preterm labor prevention.
Bandino JP; Thoppil J; Kennedy JS; Hivnor CM
Cutis; 2011 Nov; 88(5):241-3. PubMed ID: 22272488
[TBL] [Abstract][Full Text] [Related]
7. 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
Manuck TA
Semin Perinatol; 2017 Dec; 41(8):461-467. PubMed ID: 28947068
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation.
Caritis SN; Sharma S; Venkataramanan R; Rouse DJ; Peaceman AM; Sciscione A; Spong CY; Varner MW; Malone FD; Iams JD; Mercer BM; Thorp JM; Sorokin Y; Carpenter M; Lo J; Ramin S; Harper M;
Am J Obstet Gynecol; 2011 Jul; 205(1):40.e1-8. PubMed ID: 21620357
[TBL] [Abstract][Full Text] [Related]
9. Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice.
Romero R; Stanczyk FZ
Am J Obstet Gynecol; 2013 Jun; 208(6):421-6. PubMed ID: 23643669
[No Abstract] [Full Text] [Related]
10. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity.
Awwad J; Usta IM; Ghazeeri G; Yacoub N; Succar J; Hayek S; Saasouh W; Nassar AH
BJOG; 2015 Jan; 122(1):71-9. PubMed ID: 25163819
[TBL] [Abstract][Full Text] [Related]
11. Medication safety is still an issue in obstetrics 50 years after the Kefauver-Harris amendments: the case of progestogens.
O'Brien JM
Ultrasound Obstet Gynecol; 2013 Sep; 42(3):247-53. PubMed ID: 23495199
[No Abstract] [Full Text] [Related]
12. The safety of progesterone and 17-hydroxyprogesterone caproate administration for the prevention of preterm birth: an evidence-based assessment.
O'Brien JM
Am J Perinatol; 2012 Oct; 29(9):665-72. PubMed ID: 22773279
[TBL] [Abstract][Full Text] [Related]
13. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial.
Senat MV; Porcher R; Winer N; Vayssière C; Deruelle P; Capelle M; Bretelle F; Perrotin F; Laurent Y; Connan L; Langer B; Mantel A; Azimi S; Rozenberg P;
Am J Obstet Gynecol; 2013 Mar; 208(3):194.e1-8. PubMed ID: 23433324
[TBL] [Abstract][Full Text] [Related]
14. Is 17α-hydroxyprogesterone caproate contraindicated in twin gestations?
Romero R; Conde-Agudelo A
BJOG; 2015 Jan; 122(1):6-7. PubMed ID: 25280114
[No Abstract] [Full Text] [Related]
15. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
16. Prevention of Preterm Labor with 17α-Hydroxyprogesterone (17OHP) Caproate: A Comparison of Adverse Drug Reaction Rates between Compounded and Commercial Formulations.
Stone RH; Bobowski C; Milikhiker N; Anguiano RH; Mastrogiannis D
Am J Perinatol; 2017 Dec; 34(14):1436-1441. PubMed ID: 28704849
[No Abstract] [Full Text] [Related]
17. 17-alpha-hydroxyprogesterone caproate versus vaginal progesterone suppository for the prevention of preterm birth in women with a sonographically short cervix: A randomized controlled trial.
Pirjani R; Heidari R; Rahimi-Foroushani A; Bayesh S; Esmailzadeh A
J Obstet Gynaecol Res; 2017 Jan; 43(1):57-64. PubMed ID: 27775195
[TBL] [Abstract][Full Text] [Related]
18. Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.
Mainiero AD; Rouse DJ; Lopes V; Hughes BL
Obstet Gynecol; 2015 Jul; 126(1):103-8. PubMed ID: 26241262
[TBL] [Abstract][Full Text] [Related]
19. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery.
Gonzalez-Quintero VH; Cordova YC; Istwan NB; Tudela F; Rhea DJ; Romary LM; Marimon A; Desch CN; Stanziano GJ
Am J Obstet Gynecol; 2011 Sep; 205(3):275.e1-5. PubMed ID: 22071063
[TBL] [Abstract][Full Text] [Related]
20. A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth.
Shambhavi S; Bagga R; Bansal P; Kalra J; Kumar P
J Obstet Gynaecol; 2018 Aug; 38(6):800-806. PubMed ID: 29557230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
